Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies - Kobayashi, Roger H.; Gupta, Sudhir; Melamed, Isaac; Mandujano, J. Fernando; Kobayashi, Ai Lan; Ritchie, Bruce; Geng, Bob; Atkinson, Thomas Prescott; Rehman, Syed; Turpel-Kantor, Eva; Litzman, Jiří (Frontiers in Immunology, 2022)